Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

By G. Brandacher, A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, C. Winkler, E. Werner, G. Werner-Felmayer, H. Weiss, Georg Göbel and 4 more. Clinical Cancer Research, 2006

609 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/dd6217577f4706f0f6337214f18c8b29024965a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

1. D. Munn
2. A. Mellor
3. W. Zou

In Oncology

1. A. Mellor
2. D. Munn

In Psychiatry and Mental health

1. A. Mellor
2. D. Munn

Citations in the corpus

• Indoleamine 2,3-dioxygenase and tumor-induced tolerance. (2007, background): “IDO expression by tumor cells has been shown to correlate with a poor clinical prognosis in ovarian carcinoma (73), endometrial carcinoma (74), and colon carcinoma (75).”
• IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance (2016, neutral): “Tumors in this category include melanoma [42-44], colon cancer [45, 46], brain tumors [47], ovarian cancer [48], acute myelogenous leukemia [49, 50], and a number of others [51-53].”